SRNE - Sorrento inks collaborative agreement to produce NK cell-based cancer treatments

Sorrento Therapeutics ([[SRNE]] +3.9%) has entered into an additional collaborative agreement with NextGenNK Competence Center-associated research groups at the Karolinska?Institutet?(“KI”) in?Stockholm, Sweden.The collaboration aims to produce novel?cell-based therapeutics using natural killer (“NK”) cells derived from induced pluripotent stem cells (“iPSCs”).Under the agreement, Sorrento will provide know-how in the core chimeric antigen receptor (“CAR”) and dimeric antigen receptor (“DAR”) technologies and support the collaborative effort to develop new CAR-NK and DAR-NK candidates, as well as fund the translational validation of the technologies. Multiple product candidates will be developed and tested in the initial phase of the planned work.

For further details see:

Sorrento inks collaborative agreement to produce NK cell-based cancer treatments